108 related articles for article (PubMed ID: 27542980)
21. [High aldehyde dehydrogenase 1A1 (ALDH1A1) expression correlated with risk of lymph node metastasis in papillary thyroid carcinoma].
Yue C; Zhao X; Tian C; Jin Y; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):490-4. PubMed ID: 26705040
[TBL] [Abstract][Full Text] [Related]
22. Predictive Value of Sphingosine Kinase 1 Expression in Papillary Thyroid Carcinoma.
Do SI; Kim HS; Kim K; Lee H; Do IG; Kim DH; Chae SW; Sohn JH
Anticancer Res; 2017 Oct; 37(10):5399-5405. PubMed ID: 28982849
[TBL] [Abstract][Full Text] [Related]
23. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
24. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
25. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
Walts AE; Mirocha JM; Bose S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
27. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
[TBL] [Abstract][Full Text] [Related]
28. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
Shi CL; Sun Y; Ding C; Lv YC; Qin HD
Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
[TBL] [Abstract][Full Text] [Related]
29. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
30. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
31. Clinicopathological features of recurrent papillary thyroid cancer.
Zhu J; Wang X; Zhang X; Li P; Hou H
Diagn Pathol; 2015 Jul; 10():96. PubMed ID: 26168921
[TBL] [Abstract][Full Text] [Related]
32. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
[TBL] [Abstract][Full Text] [Related]
33. Septin 7 immunoexpression in papillary thyroid carcinoma: a preliminary study.
Igci YZ; Erkilic S; Arslan A
Pathol Res Pract; 2014 Jul; 210(7):426-31. PubMed ID: 24685401
[TBL] [Abstract][Full Text] [Related]
34. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma.
Roh JL; Park JW; Jeong J; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2017 Sep; 116(4):450-458. PubMed ID: 28608492
[TBL] [Abstract][Full Text] [Related]
35. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
36. BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.
Jing FJ; Liang J; Liang ZY; Meng C; Long W; Li XY; Lin YS
Chin Med J (Engl); 2013 Aug; 126(16):3013-8. PubMed ID: 23981603
[TBL] [Abstract][Full Text] [Related]
37. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.
McKelvie PA; Chan F; Yu Y; Waring P; Gresshoff I; Farrell S; Williams RA
Pathology; 2013 Dec; 45(7):637-44. PubMed ID: 24247620
[TBL] [Abstract][Full Text] [Related]
39. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
[TBL] [Abstract][Full Text] [Related]
40. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]